All In MedTech

FDA Clearance Tracker · P200037-S004

Assure Wearable Cardioverter Defibrillator (WCD) system

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 25, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 25, 2022

Approved

Time to decision

145 days

Received Jun 2, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P200037-S004
Device name
Assure Wearable Cardioverter Defibrillator (WCD) system
Applicant location
Kirkland, WA
Received
Jun 2, 2022
Decided
Oct 25, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P200037

Device type

Device class
Class III

Every decision under product code MVK

FDA's approval statement

As written in FDA's record.

Approval for a revision to the software system to version 5.0 with a feature to provide additional information to the physician about the patients health.

Source documents

Other decisions for Kestra Medical Technologies, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.